These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 34557415)

  • 1. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
    Front Oncol; 2021; 11():732214. PubMed ID: 34557415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
    Front Oncol; 2022; 12():978069. PubMed ID: 36330494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
    Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
    Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
    Front Oncol; 2022; 12():968517. PubMed ID: 36439448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.
    Huo G; Liu W; Chen P
    Front Immunol; 2022; 13():875093. PubMed ID: 35479081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than
    Tian T; Li Y; Li J; Xu H; Fan H; Zhu J; Wang Y; Peng F; Gong Y; Du Y; Yan X; He X; Cali Daylan AE; Pircher A; Neibart SS; Okuma Y; Hong MH; Huang M; Lu Y
    Transl Lung Cancer Res; 2024 Apr; 13(4):861-874. PubMed ID: 38736501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Tsukada A; Morita C; Shimizu Y; Uemura Y; Naka G; Takasaki J; Nokihara H; Izumi S; Hojo M
    Thorac Cancer; 2024 Sep; 15(25):1854-1862. PubMed ID: 39086088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.
    Liu W; Huo G; Chen P
    BMC Cancer; 2023 May; 23(1):458. PubMed ID: 37202730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.
    Chen K; Chen W; Yue R; Zhu D; Cui S; Zhang X; Jin Z; Xiao T
    Front Immunol; 2024; 15():1439624. PubMed ID: 39359729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 14. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
    Yang K; Li J; Bai C; Sun Z; Zhao L
    Front Oncol; 2020; 10():1098. PubMed ID: 32733805
    [No Abstract]   [Full Text] [Related]  

  • 16. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
    Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
    Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
    Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
    Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
    Dai L; Jin B; Liu T; Chen J; Li G; Dang J
    EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.
    Liu W; Huo G; Chen P
    Front Immunol; 2022; 13():909027. PubMed ID: 35799785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis.
    Xiao Q; Yu X; Shuai Z; Yao T; Yang X; Zhang Y
    Front Pharmacol; 2022; 13():956788. PubMed ID: 36176428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.